Mary Newman
Corporate Officer/Principal presso TAYSHA GENE THERAPIES, INC.
Profilo
Mary Newman is currently the Director at Novartis Optogenetics Research, Inc., the Director at Vedere Bio II, Inc., and a Member at Drug Information Association.
She is also the Chief Development Officer at Taysha Gene Therapies, Inc. since 2021.
Previously, she held the position of Head-Regulatory Affairs at SEQUUS Pharmaceuticals, Inc., Berlex, Inc., and BioMarin Pharmaceutical, Inc. She was also the Senior VP-Regulatory Affairs & Quality Assurance at SARcode Bioscience, Inc. from 2012 to 2013 and the Senior Vice President-Regulatory Affairs at Astellas Gene Therapies, Inc. Ms. Newman received her undergraduate and graduate degrees from Oregon State University.
Posizioni attive di Mary Newman
Società | Posizione | Inizio |
---|---|---|
TAYSHA GENE THERAPIES, INC. | Corporate Officer/Principal | 13/05/2021 |
Drug Information Association
Drug Information Association Miscellaneous Commercial ServicesCommercial Services The Drug Information Association is a non-profit multidisciplinary association that operates to promote health and well-being. The non-profit company is based in Horsham, PA. Marwan Fathallah has been the CEO of the company since 2023. | Corporate Officer/Principal | - |
Novartis Optogenetics Research, Inc.
Novartis Optogenetics Research, Inc. BiotechnologyHealth Technology Vedere Bio, Inc. develops cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss. The company was founded in June 2019 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Director/Board Member | - |
Precedenti posizioni note di Mary Newman
Società | Posizione | Fine |
---|---|---|
SARcode Bioscience, Inc.
SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA. | General Counsel | 01/04/2013 |
AUDENTES THERAPEUTICS, INC. | General Counsel | - |
SEQUUS Pharmaceuticals, Inc.
SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | General Counsel | - |
Berlex, Inc.
Berlex, Inc. Pharmaceuticals: MajorHealth Technology Berlex, Inc. manufactured pharmaceutical company. It developed novel diagnostics and therapeutics, which address unmet medical needs. It used to researches, develops, manufactures and markets ethical pharmaceuticals in five strategic areas such as female healthcare, diagnostic imaging, dermatology, oncology and therapeutics. The company was headquartered in Wayne, NJ | General Counsel | - |
BIOMARIN PHARMACEUTICAL INC. | General Counsel | - |
Formazione di Mary Newman
Oregon State University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
TAYSHA GENE THERAPIES, INC. | Health Technology |
Aziende private | 7 |
---|---|
SEQUUS Pharmaceuticals, Inc.
SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Health Technology |
Berlex, Inc.
Berlex, Inc. Pharmaceuticals: MajorHealth Technology Berlex, Inc. manufactured pharmaceutical company. It developed novel diagnostics and therapeutics, which address unmet medical needs. It used to researches, develops, manufactures and markets ethical pharmaceuticals in five strategic areas such as female healthcare, diagnostic imaging, dermatology, oncology and therapeutics. The company was headquartered in Wayne, NJ | Health Technology |
SARcode Bioscience, Inc.
SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA. | Health Technology |
Drug Information Association
Drug Information Association Miscellaneous Commercial ServicesCommercial Services The Drug Information Association is a non-profit multidisciplinary association that operates to promote health and well-being. The non-profit company is based in Horsham, PA. Marwan Fathallah has been the CEO of the company since 2023. | Commercial Services |
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Novartis Optogenetics Research, Inc.
Novartis Optogenetics Research, Inc. BiotechnologyHealth Technology Vedere Bio, Inc. develops cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss. The company was founded in June 2019 and is headquartered in Cambridge, MA. | Health Technology |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Mary Newman